REN and Fabry disease: Since treatment effects of the renin–angiotensin–aldosterone system (RAAS) blockers in patients with FD are yet elusive, we analyzed the effect of RAAS treatment on the main cardiovascular parameters assessed (LVMI, GLS, RVFWSL, RV4CSL, LaSct, LaScd, and LaSr) in migalastat- and ERT-treated patients over time (Supplementary Figure S5).